Immunic Inc (IMUX) stock saw a modest uptick, ending the day at $0.95 which represents no change from the prior close of of $0.95. The stock opened at $0.98 and touched a low of $0.92 during the day, ...

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), ...

H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $40 from $22 and keeps a Buy rating on the shares. The firm ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 ...

Fintel reports that on January 17, 2025, HC Wainwright & Co. downgraded their outlook for CECO Environmental (NasdaqGS:CECO) ...

HC Wainwright decreased their Q3 2025 EPS estimates for shares of Applied Digital in a research note issued to investors on ...

BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the“Company”), a leader in blockchain infrastructure and technology, has announced its ...

Microbot Medical Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 51.85%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...